J Menopausal Med.  2016 Aug;22(2):76-79. 10.6118/jmm.2016.22.2.76.

Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels

• Engin-Ãœstün Y
• ÇaÄŸlayan EK
• Göçmen A
• Polat MF

• KMID: 2365462
• DOI: http://doi.org/10.6118/jmm.2016.22.2.76

Abstract

OBJECTIVES
The objective of this study was to describe the levels of chemerin, irisin and apolipoprotein M (apoM) in women with postmenopausal osteoporosis.
METHODS
The study included 88 women with postmenopausal osteoporosis. Based on World Health Organization criteria, women with a T-score of ≤-2.5 were defined as osteoporotic. In this case-control study, postmenopausal women with T-score >-1 were selected as controls (n = 88) and case-matched in a 1:1 ratio based on age (within 2 years) and body mass index (BMI) (within 1.0 kg/m2). ApoM, irisin and chemerin levels were determined by a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
RESULTS
There were no significant differences in age, BMI, parity, cholesterol and apoM levels between the two groups. C-reactive protein levels were significantly increased in women with osteoporosis. Serum chemerin levels (240.1 ± 46.1 vs. 261.5 ± 50.8 ng/mL) were significantly lower in the women with osteoporosis, as compared to the controls (P = 0.004). Serum irisin levels were also decreased in women with osteoporosis (0.7 ± 0.2 vs. 0.8 ± 0.2 ng/mL; P = 0.007).
CONCLUSION
In the present study, osteoporosis was associated with decreased levels of circulating chemerin and irisin. These findings suggested that adipokines might play a role in the pathogenesis of osteoporosis.

Keyword

Adipokines; Apolipoproteins; Osteoporosis, postmenopausal

MeSH Terms

Adipokines
Apolipoproteins*
Body Mass Index
C-Reactive Protein
Case-Control Studies
Cholesterol
Enzyme-Linked Immunosorbent Assay
Female
Humans
Osteoporosis
Osteoporosis, Postmenopausal*
Parity
World Health Organization
Adipokines
Apolipoproteins
C-Reactive Protein
Cholesterol

Reference

1. Upadhyay J, Farr OM, Mantzoros CS. The role of leptin in regulating bone metabolism. Metabolism. 2015; 64:105–113.

2. Scotece M, Conde J, Abella V, López V, Pino J, Lago F, et al. Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery? Expert Opin Drug Discov. 2014; 9:945–957.

3. Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96:2703–2713.

4. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res. 2010; 25:1711–1723.

5. Arias-Loste MT, Ranchal I, Romero-Gómez M, Crespo J. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci. 2014; 15:23163–23178.

6. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos Int. 2014; 25:1633–1642.

7. Palermo A, Strollo R, Maddaloni E, Tuccinardi D, D'Onofrio L, Briganti SI, et al. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin Endocrinol (Oxf). 2015; 82:615–619.

8. Zhang J, Cheng J, Tu Q, Chen J. Effects of irisin on bone metabolism and its signal mechanism. J Bone Miner Res. 2013; 28:Suppl 1. SA0185.

9. Colaianni G, Cuscito C, Mongelli T, Oranger A, Mori G, Brunetti G, et al. Irisin enhances osteoblast differentiation in vitro. Int J Endocrinol. 2014; 2014:902186.

10. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148:4687–4694.

11. He J, Li JC, Xie H, Xu ZH, Sun YW, Shan Q. Serum chemerin levels in relation to osteoporosis and bone mineral density: A case-control study. Dis Markers. 2015; 2015:786708.

12. Memon AA, Bennet L, Zöller B, Wang X, Palmér K, Dahlbäck B, et al. The association between apolipoprotein M and insulin resistance varies with country of birth. Nutr Metab Cardiovasc Dis. 2014; 24:1174–1180.

13. Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, Rodan GA, et al. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ. 2004; 11:Suppl 1. S108–S118.